Market Overview

Why MacroGenics Is Moving Today


MacroGenics Inc (NASDAQ: MGNX) shares are moving on Friday.

The company announced the FDA has granted Orphan Drug Designation to Margetuximab in the U.S. for gastric cancer.

Macrogenics is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates.

MacroGenics's stock was trading up 0.20% at $20.52 on Friday. The stock has a 52-week high of $29.50 and a 52-week low of $4.04.

Related Links:

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually


Related Articles (MGNX)

View Comments and Join the Discussion!

Posted-In: why it's movingNews FDA